Stay updated with breaking news from Christopherm Chipman. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its...
--VRPX Intranasal Cannabidiol Product Candidate for Management of Epilepsy in Children and Adults--BERWYN, Pa.--(BUSINESS WIRE)--#pharma--Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress di...
--Company Highlights Development Timelines for Product Candidates--BERWYN, Pa.--(BUSINESS WIRE)--#earnings--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX) a company specializing in developing non-addictive product candidates for pain management, post-traumatic stress disorder, central nervou...
Virpax Pharmaceuticals Expands AnQlar™ Development and Commercialization Rights Through Worldwide Licensing Agreement - AnQlar ™ Has Previously Demonstrated... | March 20, 2022
- AnQlar Has Previously Demonstrated Antiviral Activity Against Influenza and SARS-CoV-2 in Three Preclinical Studies - -- The FDA has indicated that Virpax may pursue an NDA drug approval with